C099 | IMPROVED METABOLIC PROFILE IN PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: A POOLED ANALYSIS OF PROSPECTIVE CLINICAL TRIALS
Background: Serum albumin is a prognostic marker in patients with myelofibrosis (MF), with levels <4.3 g/dL associated with inferior survival [Tefferi A, et al. Blood Adv. 2018]. Retrospective data suggest that ruxolitinib is associated with increases in albumin [Kuykendall AT, et al. JCO Precision...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Ferrata Storti Foundation
2025-09-01
|
| Серія: | Haematologica |
| Онлайн доступ: | https://haematologica.org/article/view/12763 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|